JMCP Key Subjects

August 2014 - Volume 20 Issue 8

Use of an Early Disease-Modifying Drug Adherence Measure to Predict Future Adherence in Patients with Multiple Sclerosis
BACKGROUND: Patients with multiple sclerosis (MS) who are adherent to their treatment regimens are less likely to experience relapses and the cost associated with relapse. Pharmacists whose practice involves these specialty pharmaceuticals used to treat MS are striving for ways to improve outcomes by achieving treatment adherence in their patients. Specialty pharmacies have reported higher adherence rates than traditional pharmacies, which may translate to improved outcomes. Identifying patients who warrant increased adherence intervention is critical. Models using administrative health care claims to predict adherence have typically included demographic characteristics, comorbidities, and/or previous consumption of health care resources. Addition of a measure of early adherence may improve the ability to predict future adherence outcomes. OBJECTIVE: To evaluate early adherence with disease-modifying drugs (DMDs) as a predictor of future adherence in patients with MS. METHODS: The first DMD claim (i.e., index event) for adult MS patients (aged ≥18 years and aged ≤... READ THE FULL ARTICLE »


| Volume 20 , No. 8
Content for class "break" Goes Here